Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMB NASDAQ:NBRV NYSE:PRME NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMBINmune Bio$2.36+2.6%$6.54$1.89▼$11.64$54.25M1.34804,470 shs1.95 million shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs80 shsPRMEPrime Medicine$4.54+10.7%$1.78$1.11▼$6.75$596.08M2.331.66 million shs8.74 million shsVYGRVoyager Therapeutics$3.47+9.1%$3.20$2.65▼$9.55$175.97M0.85484,547 shs1.11 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMBINmune Bio0.00%+10.05%-69.82%-69.86%-70.09%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%PRMEPrime Medicine+7.89%+50.18%+142.60%+228.00%-25.32%VYGRVoyager Therapeutics+4.61%+1.92%-10.17%+2.25%-59.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMBINmune Bio1.5823 of 5 stars3.30.00.00.02.01.70.6NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRMEPrime Medicine4.0582 of 5 stars4.41.00.00.03.85.00.6VYGRVoyager Therapeutics3.8022 of 5 stars3.61.00.04.62.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMBINmune Bio 2.57Moderate Buy$18.40679.66% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/APRMEPrime Medicine 2.75Moderate Buy$10.08122.10% UpsideVYGRVoyager Therapeutics 3.13Buy$13.39285.88% UpsideCurrent Analyst Ratings BreakdownLatest NBRV, PRME, INMB, and VYGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMBINmune Bio$10K5,564.88N/AN/A$1.45 per share1.63NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00PRMEPrime Medicine$3.85M154.99N/AN/A$1.37 per share3.31VYGRVoyager Therapeutics$80M2.40N/AN/A$5.49 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/AVYGRVoyager Therapeutics-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)Latest NBRV, PRME, INMB, and VYGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025VYGRVoyager Therapeutics-$0.48N/AN/AN/A$9.50 millionN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMBINmune BioN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4531.85%N/AN/A N/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMBINmune BioN/A2.642.64NBRVNabriva Therapeutics0.120.850.52PRMEPrime MedicineN/A6.506.50VYGRVoyager TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMBINmune Bio12.72%NBRVNabriva Therapeutics0.27%PRMEPrime Medicine70.37%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipINMBINmune Bio35.70%NBRVNabriva Therapeutics1.63%PRMEPrime Medicine22.93%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMBINmune Bio1023.58 million15.17 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableVYGRVoyager Therapeutics10055.34 million51.80 millionOptionableNBRV, PRME, INMB, and VYGR HeadlinesRecent News About These CompaniesBrokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39July 8 at 2:39 AM | americanbankingnews.comRNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'July 7 at 5:45 AM | itv.comIAtlas Announces New Canadian Arctic Expedition Aboard World VoyagerJuly 6 at 4:45 AM | cruiseindustrynews.comCWith Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-WalletsJuly 5, 2025 | travelmole.comTVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesJuly 5, 2025 | marketbeat.comAnt International launches Alipay+ Voyager, an AI-powered travel assistant inside e-walletsJuly 3, 2025 | walastech.comWVYGR Voyager Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMajor Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With PaintJune 20, 2025 | theaviationist.comTProtesters Vandalize RAF Voyager Tankers In Palestine ProtestJune 20, 2025 | aviationweek.comAVoyager Technologies Soars with IPO SuccessJune 14, 2025 | devdiscourse.comDSpace Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss ExpansionJune 12, 2025 | devdiscourse.comDVoyager Technologies Rises in Debut, Signaling Improving IPO MarketJune 12, 2025 | msn.comVoyager soars 82% on first day of trading as defense tech boomsJune 12, 2025 | msn.comInvestor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOsJune 11, 2025 | msn.comVoyager Technologies' Shares More Than Double in NYSE DebutJune 11, 2025 | marketwatch.comVoyager Technologies Shares Soar In Market DebutJune 11, 2025 | news.crunchbase.comNSpace tech firm Voyager valued at $3.8 billion as shares surge in NYSE debutJune 11, 2025 | aol.comAVoyager raises $383 million from upsized IPOJune 11, 2025 | spacenews.comSSpace and defense tech firm Voyager raises $382.8 million in IPOJune 11, 2025 | fastcompany.comFVoyager Technologies Valued at $3.8 Billion in Stellar NYSE DebutJune 11, 2025 | msn.comVoyager Technologies’ IPO shows investors are still hot on space stocks, despite a mixed historyJune 11, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBRV, PRME, INMB, and VYGR Company DescriptionsINmune Bio NASDAQ:INMB$2.36 +0.06 (+2.61%) Closing price 04:00 PM EasternExtended Trading$2.34 -0.02 (-0.85%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Prime Medicine NYSE:PRME$4.54 +0.44 (+10.73%) Closing price 04:00 PM EasternExtended Trading$4.60 +0.05 (+1.21%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Voyager Therapeutics NASDAQ:VYGR$3.47 +0.29 (+9.12%) Closing price 04:00 PM EasternExtended Trading$3.46 -0.02 (-0.43%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
